Ohsu Knight Cancer Institute
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
Phase 2
Not yet recruiting
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Lumbar Puncture
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT06895473
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Vaccine Responses in Patient with Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Recruiting
- Conditions
- Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular LymphomaMantle Cell LymphomaMultiple MyelomaPrimary Mediastinal Large B-Cell LymphomaSmall Lymphocytic Lymphoma
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT06784167
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial
Not Applicable
Recruiting
- Conditions
- Clinical Stage IA Cutaneous Melanoma AJCC v8Clinical Stage IB Cutaneous Melanoma AJCC v8
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1000
- Registration Number
- NCT06673095
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Advanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaStage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage III Prostate Cancer AJCC v8
- Interventions
- Procedure: BiopsyProcedure: Bone ScanProcedure: EchocardiographyProcedure: Multigated Acquisition ScanOther: Survey AdministrationProcedure: Biospecimen Collection
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer
Recruiting
- Conditions
- Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm
- Interventions
- Other: Non-Interventional Study
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06562777
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
Phase 2
Recruiting
- Conditions
- High Risk Prostate CarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Localized Prostate Adenocarcinoma
- Interventions
- Drug: Gonadotropin Releasing Hormone Agonists and AntagonistsProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Bone Scan
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT06528210
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Venetoclax in Combination with Cladribine and Cytarabine Alternating with Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Phase 2
Recruiting
- Conditions
- Acute Myeloid LeukemiaAcute Monocytic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Lumbar PunctureProcedure: Multigated Acquisition ScanOther: Questionnaire Administration
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06504459
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2
Withdrawn
- Conditions
- Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma
- Interventions
- Procedure: ElectrocardiographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Biospecimen CollectionProcedure: Computed Tomography
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT06398587
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanOther: Questionnaire Administration
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT06357182
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma
Phase 1
Not yet recruiting
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: FDG-Positron Emission TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT06357676
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States